Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1NSCLC Harboring NRG1 Fusion 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × zenocutuzumab × Thoracic × Clear all
NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Partner Therapeutics, Inc.

Phase 2 Active not recruiting
250 enrolled 2 FDA
GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡